Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynami ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator: Steven Hepp
Phone: 802.793.3352
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Steven Hepp
Phone: 802.793.3352
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Mary Rose Silvas
Phone: 713.441.1952
The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
The purpose of this exploratory biomarker study is to further our understanding of the role of CSCs in lung cancer metastasis by examining the CSC population in metastatic tissue. ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >
Status: Enrolling
Investigator: Eric Bernicker
Study Coordinator:
Phone:
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Daniel (cancer) Le (cancer)
Phone: 346.238.5655
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Lacey Burey
Phone: 713.441.1159
The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for lar ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Mary Rose Silvas
Phone: 713.441.1952
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >
Status: Enrolling
Investigator: Kirk Heyne
Study Coordinator: Caroline Fitzgerald
Phone: 713.441.3250
The purpose of this study is to investigate nivolumab combined with Debio 1143. The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used wi ... Read more >
